Molecular Basis of CYP2D6-Mediated N-Dealkylation: Balance between Metabolic Clearance Routes and Enzyme Inhibition

被引:15
作者
Bonn, Britta [1 ,2 ]
Masimirembwa, Collen M. [1 ,3 ]
Aristei, Yasmin [4 ]
Zamora, Ismael [5 ,6 ]
机构
[1] AstraZeneca R&D, Discovery DMPK & Bioanalyt Chem, SE-43183 Molndal, Sweden
[2] Univ Gothenburg, Dept Chem, Gothenburg, Sweden
[3] African Inst Biomed Sci & Technol, Harare, Zimbabwe
[4] Univ Perugia, Dept Chem, Lab Chemometr & Chemoinformat, I-06100 Perugia, Italy
[5] Univ Pompeu Fabra, Inst Municipal Invest Med, Barcelona, Spain
[6] Soc Ltd, Lead Mol Design, San Cugat Del Valles, Spain
关键词
D O I
10.1124/dmd.108.022376
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
N-Dealkylation is a commonly observed metabolic reaction for drugs containing secondary and tertiary amines. On searching the literature, it is obvious that this reaction is far less common among cytochrome P450 2D6 catalyzed reactions compared with other cytochromes P450. The CYP2D6 pharmacophore and characteristic features in the active site cavity suggest a favored substrate orientation that prevents N-dealkylation from occurring. In this study, the literature was searched for N-dealkylated and non-N-dealkylated CYP2D6 substrates. The hypothesis that was suggested and confirmed demonstrated that N-dealkylation occurs by this enzyme when the preferred site of metabolism is blocked toward other oxidative metabolic pathways. An interesting observation was also that addition of stable groups at preferred sites of metabolism generally improved the metabolic stability but also resulted in retained or increased inhibition of the enzyme. In addition, the effect of pH on N- and O-dealkylation of dextromethorphan was shown to be consistent with the hypothesis that an ionized amino function favored substrate dockings resulting in O-dealkylation.
引用
收藏
页码:2199 / 2210
页数:12
相关论文
共 47 条
  • [1] State-of-the-art tools for computational site of metabolism predictions: Comparative analysis, mechanistical insights, and future applications
    Afzelius, Lovisa
    Arnby, Catrin Hasselgren
    Broo, Anders
    Carlsson, Lars
    Isaksson, Christine
    Jurva, Ulrik
    Kjellander, Britta
    Kolmodin, Karin
    Nilsson, Kristina
    Raubacher, Florian
    Weidolf, Lars
    [J]. DRUG METABOLISM REVIEWS, 2007, 39 (01) : 61 - 86
  • [2] CYP2C9 structure-metabolism relationships:: Substrates, inhibitors, and metabolites
    Ahlstrom, Marie M.
    Ridderstrom, Marianne
    Zamora, Ismael
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2007, 50 (22) : 5382 - 5391
  • [3] Involvement of CYP2D6 in the in vitro metabolism of amphetamine, two N-alkylamphetamines and their 4-methoxylated derivatives
    Bach, MV
    Coutts, RT
    Baker, GB
    [J]. XENOBIOTICA, 1999, 29 (07) : 719 - 732
  • [4] A common reference framework for analyzing/comparing proteins and ligands. Fingerprints for ligands and proteins (FLAP): Theory and application
    Baroni, Massimo
    Cruciani, Gabriele
    Sciabola, Simone
    Perruccio, Francesca
    Mason, Jonathan S.
    [J]. JOURNAL OF CHEMICAL INFORMATION AND MODELING, 2007, 47 (02) : 279 - 294
  • [5] Role of individual human cytochrome P450 enzymes in the in vitro metabolism of hydromorphone
    Benetton, SA
    Borges, VM
    Chang, TKH
    Mcerlane, KM
    [J]. XENOBIOTICA, 2004, 34 (04) : 335 - 344
  • [6] INVOLVEMENT OF CYP2D6, CYP3A4, AND OTHER CYTOCHROME-P-450 ISOZYMES IN N-DEALKYLATION REACTIONS
    COUTTS, RT
    SU, P
    BAKER, GB
    [J]. JOURNAL OF PHARMACOLOGICAL AND TOXICOLOGICAL METHODS, 1994, 31 (04) : 177 - 186
  • [7] Microtiter plate assays for inhibition of human, drug-metabolizing cytochromes P450
    Crespi, CL
    Miller, VP
    Penman, BW
    [J]. ANALYTICAL BIOCHEMISTRY, 1997, 248 (01) : 188 - 190
  • [8] Identification of metabolic pathways involved in the biotransformation of tolperisone by human microsomal enzymes
    Dalmadi, B
    Leibinger, J
    Szeberényi, S
    Borbás, T
    Farkas, S
    Szombathelyi, Z
    Tihanyi, K
    [J]. DRUG METABOLISM AND DISPOSITION, 2003, 31 (05) : 631 - 636
  • [9] A novel approach to predicting P450 mediated drug metabolism. CYP2D6 catalyzed N-dealkylation reactions and qualitative metabolite predictions using a combined protein and pharmacophore model for CYP2D6
    de Groot, MJ
    Ackland, MJ
    Horne, VA
    Alex, AA
    Jones, BC
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 1999, 42 (20) : 4062 - 4070
  • [10] Theoretical investigation of substrate specificity for cytochromes p450 IA2, p450 IID6 and p450 IIIA4
    De Rienzo, F
    Fanelli, F
    Menziani, MC
    De Benedetti, PG
    [J]. JOURNAL OF COMPUTER-AIDED MOLECULAR DESIGN, 2000, 14 (01) : 93 - 116